Literature DB >> 18271901

What is the optimal serum lithium level in the long-term treatment of bipolar disorder--a review?

W E Severus1, N Kleindienst, F Seemüller, S Frangou, H J Möller, W Greil.   

Abstract

OBJECTIVES: There is substantial uncertainty about the most efficacious serum lithium level for the long-term treatment of bipolar disorder (BD). This review focuses on the available evidence taking into consideration the effects of previous lithium history, changes in lithium level and polarity of relapse or recurrence.
METHODS: We conducted a MEDLINE search, using the MeSH Terms 'bipolar disorder' and 'lithium' together with 'randomized controlled trial' or 'controlled clinical trial' covering the time span from 1966 to March 2006. We only included studies reporting on the long-term treatment of mood disorders where patients with BD were examined as a separate group and were assigned to precisely specified target ranges of lithium level.
RESULTS: The minimum efficacious serum lithium level in the long-term treatment of bipolar disorder was 0.4 mmol/L with optimal response achieved at serum levels between 0.6-0.75 mmol/L. Lithium levels >0.75 mmol/L may not confer additional protection against overall morbidity but may further improve control of inter-episode manic symptoms. Abrupt reduction of serum levels of more than 0.2 mmol/L was associated with increased risk of relapse.
CONCLUSIONS: In the long-term treatment of bipolar disorder clinicians should initially aim for serum lithium levels of 0.6-0.75 mmol/L, while higher levels may benefit patients with predominantly manic symptoms.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18271901     DOI: 10.1111/j.1399-5618.2007.00475.x

Source DB:  PubMed          Journal:  Bipolar Disord        ISSN: 1398-5647            Impact factor:   6.744


  27 in total

1.  An exploratory study of responses to low-dose lithium in African Americans and Hispanics.

Authors:  Jodi Gonzalez Arnold; Stephanie Salcedo; Terrence A Ketter; Joseph R Calabrese; Dustin J Rabideau; Andrew A Nierenberg; Melissa Bazan; Andrew C Leon; Edward S Friedman; Dan Iosifescu; Louisa G Sylvia; Michael Ostacher; Michael Thase; Noreen A Reilly-Harrington; Charles L Bowden
Journal:  J Affect Disord       Date:  2015-03-14       Impact factor: 4.839

2.  [Acute and long-term treatment for bipolar depression].

Authors:  H Grunze; S Dargel
Journal:  Nervenarzt       Date:  2010-05       Impact factor: 1.214

Review 3.  Optimal frequency of lithium administration in the treatment of bipolar disorder: clinical and dosing considerations.

Authors:  Gin S Malhi; Michelle Tanious
Journal:  CNS Drugs       Date:  2011-04       Impact factor: 5.749

4.  Revisiting Lithium: Utility for Behavioral Stabilization in Adolescents and Adults with Autism Spectrum Disorder.

Authors:  Mark Mintz; Emma Hollenberg
Journal:  Psychopharmacol Bull       Date:  2019-06-20

5.  Toxicity and photosensitizing assessment of gelatin methacryloyl-based hydrogels photoinitiated with lithium phenyl-2,4,6-trimethylbenzoylphosphinate in human primary renal proximal tubule epithelial cells.

Authors:  Alexander K Nguyen; Peter L Goering; Vytas Reipa; Roger J Narayan
Journal:  Biointerphases       Date:  2019-05-03       Impact factor: 2.456

Review 6.  Lithium: updated human knowledge using an evidence-based approach. Part II: Clinical pharmacology and therapeutic monitoring.

Authors:  Etienne Marc Grandjean; Jean-Michel Aubry
Journal:  CNS Drugs       Date:  2009       Impact factor: 5.749

7.  Lithium dosing strategies during pregnancy and the postpartum period.

Authors:  Richard Wesseloo; André I Wierdsma; Inge L van Kamp; Trine Munk-Olsen; Witte J G Hoogendijk; Steven A Kushner; Veerle Bergink
Journal:  Br J Psychiatry       Date:  2017-07       Impact factor: 9.319

8.  Knockin of mutant PIK3CA activates multiple oncogenic pathways.

Authors:  John P Gustin; Bedri Karakas; Michele B Weiss; Abde M Abukhdeir; Josh Lauring; Joseph P Garay; David Cosgrove; Akina Tamaki; Hiroyuki Konishi; Yuko Konishi; Morassa Mohseni; Grace Wang; D Marc Rosen; Samuel R Denmeade; Michaela J Higgins; Michele I Vitolo; Kurtis E Bachman; Ben Ho Park
Journal:  Proc Natl Acad Sci U S A       Date:  2009-02-05       Impact factor: 11.205

9.  Transcriptional analysis of sodium valproate in a serotonergic cell line reveals gene regulation through both HDAC inhibition-dependent and independent mechanisms.

Authors:  Priyanka Sinha; Simone L Cree; Allison L Miller; John F Pearson; Martin A Kennedy
Journal:  Pharmacogenomics J       Date:  2021-03-01       Impact factor: 3.550

10.  Comparison of three a-priori models in the prediction of serum lithium concentration.

Authors:  Rajiv Radhakrishnan; Milanduth Kanigere; Jayakumar Menon; Sam Calvin; Krishnamachari Srinivasan
Journal:  Indian J Pharmacol       Date:  2012-03       Impact factor: 1.200

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.